New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 19, 2013
05:48 EDTSNY, SHPG, VPHMViroPharma downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded ViroPharma (VPHM) citing valuation and raised its price target for shares to $43 from $38. The firm believes a takeover of ViroPharma by either Shire (SHPG) or Sanofi (SNY), as reported by Bloomberg, makes sense and is fairly likely.
News For VPHM;SHPG;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 2, 2015
07:05 EDTSHPGSangamo and Shire restructure collaboration to accelerate development of ZFP
Subscribe for More Information
September 1, 2015
16:17 EDTSNYArdelyx regains NaP2b program from Sanofi
Subscribe for More Information
09:01 EDTSNYRegeneron and Sanofi announces Praluent Phase 3 data
Regeneron (REGN) and Sanofi (SNY) announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia patients included in the ODYSSEY clinical trial program, Praluent significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol. This analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C compared to placebo in both arms. Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.
August 31, 2015
09:07 EDTSNYSanofi, Google Life Sciences to collaborate to improve diabetes health outcomes
Subscribe for More Information
06:35 EDTSNYAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTSNYAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
16:29 EDTSHPGStocks end volatile week higher as China whipsaws U.S. market
Subscribe for More Information
16:17 EDTSHPGOn The Fly: Top stock stories for Friday
Stocks slipped at the open as the futures once again were influenced by the volatile overnight trading session in China. The averages began to recover shortly after the open and turned mixed by midday. Comments from Fed Vice Chairman Stanley Fisher about the central bank being open to a possible rate hike in September took some momentum out of the market. As the volume slowed and the news flow went silent, the volatility increased and the averages headed lower only to rebound before the close, but the trading was still remarkably calm when compared to the wide swings seen in the market in the earlier sessions of this week. ECONOMIC EVENTS: In the U.S., personal income rose 0.4% in July, as expected, with consumer spending up 0.3%, which was below the 0.4% consensus growth forecast. The University of Michigan consumer sentiment reading for August was revised down to 91.9 from the 92.9 preliminary reading, versus expectations for it to be bumped up to 93.0. Baker Hughes reported the U.S. rig count is down 8 rigs from last week to 877. WTI crude oil prices added another 6% today to yesterday's 10% rally, closing at $45.22 a barrel on Friday. U.S. crude closed with a weekly gain of 11.8%, marking its first advance in 10 weeks and best week in six years. The Federal Reserve may still raise its benchmark interest rate in September, Fed vice chairman Stanley Fischer said in an interview with CNBC, noting that Fed committee members "haven't made a decision yet" and have "time to wait and see," because the next policy-making meeting won't happen until the middle of next month. COMPANY NEWS: Shares of cancer drug maker ARIAD (ARIA) surged $2.91, or 41.69%, to $9.89 after Bloomberg reported that industry peer Baxalta (BXLT) is in takeover talks with the smaller company to boost its oncology pipeline. Baxalta, which had recently turned down a merger offer from Shire (SHPG), fell $1.18, or 3.24%, to $35.25 following the report... In other pharmaceutical industry M&A news, Mylan (MYL) shareholders voted to approve the company's proposed acquisition of Perrigo (PRGO) and the related issuance of Mylan ordinary shares. Afterward, Perrigo CEO Joseph Papa said he was confident that most of his company's shareholders believe that Mylan's offer substantially undervalues Perrigo and would dilute its "growth profile and superior valuation"... Video game maker Activision Blizzard (ATVI) and airline owner United Continental (UAL) both advanced sharply, rising 4.62% and 6.93%, respectively, after each had their shares selected to join the S&P 500. Activision will replace Pall Corp. (PLL) in the S&P 500 after the close of trading tonight, while United will replace Hospira (HSP) in the index after the close of trading on Wednesday, September 2. MAJOR MOVERS: Among the notable gainers was Big Lots (BIG), which advanced $6.58, or 15.67%, to $48.58 after the discount retailer reported better than expected quarterly results and lifted its fiscal year guidance. Among the noteworthy losers after their quarterly reports were video game retailer GameStop (GME), which slid $3.71, or 8.03%, to $42.49, and design software and services company Autodesk (ADSK), which fell $2.48, or 4.96%, to $47.52. INDEXES: The Dow fell 11.76, or 0.07%, to 16,643.01, the Nasdaq gained 15.62, or 0.32%, to 4,828.33, and the S&P 500 advanced 1.21, or 0.06%, to 1,988.87.
14:40 EDTSHPGBaxalta in talks to acquire ARIAD, Bloomberg reports
Subscribe for More Information
13:43 EDTSHPGBlood cancer drug makers rise amid speculation of Baxalta talks
Subscribe for More Information
12:36 EDTSHPGARIAD jumps 15% after report on Baxalta pursuit of oncology drug maker
Subscribe for More Information
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTSNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
August 25, 2015
16:43 EDTSHPGOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
09:03 EDTSHPGAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
07:06 EDTSHPGShire reaches CINRYZE agreement with Sanquin Blood Supply
Subscribe for More Information
August 24, 2015
18:55 EDTSHPGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTSHPGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
August 21, 2015
09:38 EDTSHPGUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 20, 2015
11:33 EDTSNYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use